Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications...
Life-saving naloxone, an emergency drug used to reverse a potentially fatal opioid overdose, is now available to businesses and organizations in Texas for online purchase and delivery at www.NaloxoneExchange.com, the company Fiduscript announced Thursday.
NanoSphere Health Sciences Inc. is pleased to announce work has begun on the production facility for NanoSphere’s products in Canada, based at the Delta 9 Cannabis Inc. (TSXV: NINE) (OTC: VRNDF) facility in Winnipeg, Manitoba.
Promega Corporation’s new Maxwell® RSC miRNA Plasma and Serum Kit offers oncology and translational researchers an easy and automated protocol to purify total circulating RNA, including miRNA, from plasma, serum and enriched exosomes for advance techniques such as NGS or ddPCR.
Grifols has earned the honor of 2019 Category Leader in IV Workflow Management in the 2019 Best in KLAS: Software & Services report for its PharmacyKeeper Verification product.
ROKIT Healthcare, Inc., a regenerative medicine company focused on the development of novel regenerative therapeutic strategies using three-dimensional (3D) biofabrication technologies for treatment of various medical conditions including dermatological, orthopedic, and..
Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings Inc., has received Breakthrough Device Designation (formerly known as Expedited Access Pathway (EAP) designation) from the Center of Devices and...
Global warming is a serious problem, mainly because of the increase in greenhouse gases such as methane and carbon oxide (CO2), as well as society's dependence on petroleum products. Large amounts of money have been spent to research and develop new kinds of energy sources instead of petroleum-based fuel.
Sun Pharmaceutical Industries, Inc. (SPII), a wholly owned subsidiary of Sun Pharmaceutical Industries, Ltd. is voluntarily recalling three lots of Vecuronium Bromide for Injection, 10 mg (lyophilized powder), and one lot of Vecuronium Bromide for Injection, 20 mg (lyophilized powder) to the hospital level.
Easy availability of donor tissue, absence of scars, short recovery times: several advantages have made lipofilling a promising technique for breast augmentation, asymmetry correction and reconstruction, but fat resorption can severely limit results.